

PRODUCT INFORMATION



Lomitapide-d₈

Item No. 28764

CAS Registry No.: 2459377-96-7

Formal Name: N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl-d₈]-9H-fluorene-9-carboxamide

MF: C₃₉H₂₉D₈F₆N₃O₂

FW: 701.8

Chemical Purity: ≥98% (Lomitapide)


Deuterium

Incorporation: ≥99% deuterated forms (d₁-d₈); ≤1% d₀

Supplied as: A crystalline solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Lomitapide-d₈ is intended for use as an internal standard for the quantification of lomitapide (Item No. 10009610) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Lomitapide-d₈ is supplied as a crystalline solid. A stock solution may be made by dissolving the lomitapide-d₈ in the solvent of choice, which should be purged with an inert gas. Lomitapide-d₈ is soluble in acetonitrile.

Description

Lomitapide is an inhibitor of microsomal triglyceride transfer protein (MTTP; IC₅₀ = 0.5 nM in a triglyceride transfer assay).¹ It inhibits apolipoprotein B (ApoB) secretion in HepG2 cells (EC₅₀ = 0.8 nM). Lomitapide inhibits triglyceride secretion in fasted rats (ED₅₀ = 0.19 mg/kg, p.o.) and reduces total plasma cholesterol levels in hamsters (ED₅₀ = 2.4 mg/kg). It also decreases plasma cholesterol and triglyceride levels in the Watanabe-heritable hyperlipidemic (WHHL) rabbit model of homozygous familial hypercholesterolemia when administered at a dose of 10 mg/kg. Formulations containing lomitapide have been used as an adjunct to a low-fat diet and other lipid-lowering treatments in the treatment of homozygous familial hypercholesterolemia.

Reference

1. Wetterau, J.R., Gregg, R.E., Harrity, T.W., *et al.* An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. *Science* **282**(5389), 751-754 (1998).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 03/08/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM